Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 65 от 222

Recruiting

Amino Acid Oxidation of Whole-Food Protein: a Dose-Response Crossover Trial in Young Adults

Protein Metabolism

The purpose of this study is to assess the amino acid oxidation dose-response relationship of ingested whole-food protein in healthy adults. In a randomized, crossover design, 20 young, healthy adult males and females aged 18-35 years, will consume a dinner consisting of 0.32, 0.74, and 1.32 g protein･kg BM-1 (corresponding to 1, 2, and 4 minced beef patties, respectively) during 3 separate experimental trials.The main study endpoint is the amino acid oxidation of ingested protein over a 24-h period.

Начало: 01.11.2025 Край: 01.03.2027 Възраст: 18–35 г.

Netherlands Maastricht University Medical Center NCT07547176

Recruiting

CCM OPEN HF Registry

Heart Failure

The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.

Начало: 01.11.2025 Край: 01.08.2036 Възраст: от 18 г.

United States Impulse Dynamics NCT07112924

Recruiting

CAIX PET/ CT Guided Radiation Therapy in CcRCC.

Radiation Therapy Metastatic Renal Cancer Recurrent Renal Cell Cancer

This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET/CT imaging (FDG PET/CT and a CAIX-targeted PET/CT) to map disease sites. When feasible, PET/CT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: \~70).

Начало: 01.11.2025 Край: 31.12.2030 Възраст: от 18 г.

China Peking University First Hospital NCT07540260

Recruiting

Out-patiente Management for Gangrenous Acute Appendicitis: The PENDI-CSI II Randomized Clinical Trial.

Appendicitis Acute Gangrenous Appendicitis

PHASE II-III CLINICAL TRIAL TO EVALUATE THE SAFETY, EFFECTIVENESS AND EFFICIENCY OF DISCHARGE TO OUTPATIENT SURGERY IN PATIENTS WITH ACUTE GANGRENOUS APPENDICITIS UNDERGOING EMERGENCY SURGERY.

Начало: 01.11.2025 Край: 01.11.2027 Възраст: от 14 г.

Spain Fundación Pública Andaluza para la gestión de la Invest NCT07521969

Recruiting

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

Ulcerative Colitis, Pediatric Inflammatory Bowel Diseases Crohn Disease

The purpose of the study is to compare the clinical effectiveness and safety of newer inflammatory bowel disease (IBD) medications in anti-tumor necrosis factor (TNF) refractory patients with pediatric IBD (PIBD). Refractory means that there was no clinical response to anti-tumor necrosis factor (TNF) drugs or that the if there was a response, it is no longer present. The main question this study aims to answer is: Are the newer medications used to treat IBD just as safe and effective for treating IBD in children. Participants will already be taking these newer medications as assigned by their regular health care provider.Participants' care will be managed by their regular healthcare provider as part of usual (standard) care for those with PIBD. While taking these medications, participants will be asked to answer questions about their symptoms and health periodically over the course of the study.

Начало: 01.11.2025 Край: 01.09.2028 Възраст: 1–18 г.

United States University of North Carolina, Chapel Hill NCT07198113

Recruiting

Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).

Acute Ischemic Stroke (AIS)

The primary objective of this study is to collect real-world performance and safety data on the Penumbra System in a patient population with acute ischemic stroke (AIS)

Начало: 01.11.2025 Край: 01.12.2027 Възраст: 18–75 г.

Australia, France, Germany +1 Penumbra Inc. NCT07107022

Recruiting

Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.

Pulmonary Hypertension Due to Left Heart Disease Pulmonary Hypertension (PH) Heart Failure

Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin. Focusing on dysregulation of the BMPR2-activin pathway, a key regulator of vascular homeostasis, this project uses a multimodal approach combining molecular biology, advanced cardiac imaging, and histology. Its aim is to determine the role of the BMPR2-activin pathway in the development and regression of PH-LHD. We will conduct a prospective observational study with 1-year follow-up in 150 heart failure patients of different etiologies undergoing hemodynamic assessment. Clinical parameters, biomarkers, molecular profiles, and hemodynamic/echocardiographic variables will be analyzed. A nested substudy in 40 heart transplant candidates will include thoracic CT for vascular morphometric analysis and histological correlation in explanted hearts versus healthy controls. We will also assess reversibility of vascular remodeling one year after transplantation. Results may redefine PH-LHD classification, enable phenotypic precision-medicine models, guide targeted therapies such as activin inhibitors, and refine transplant criteria in combined pulmonary hypertension.

Начало: 01.11.2025 Край: 31.12.2028 Възраст: от 18 г.

Spain Hospital General Universitario Gregorio Marañon NCT07537517

Recruiting

Oral Microbiome in Carotid Atherosclerosis

Atherosclerosis Cardiovascular Disease Atherosclerosis of Artery Carotid Artery Plaque Periodontitis +1

The goal of this observational study, called OMICA (Oral Microbiome in Carotid Atherosclerosis), is to learn how bacteria living in the mouth may influence the development and stability of plaques in the carotid arteries, which supply blood to the brain. Plaque buildup in these arteries can lead to stroke. Researchers want to understand whether certain oral bacteria are linked to plaque vulnerability, meaning a higher chance that the plaque will rupture and cause a stroke. The study will include a cohort of adults scheduled for carotid endarterectomy at Semmelweis University. Participants will be enrolled in the Semmelweis University Carotid Biobank project. The main questions the study aims to answer are: Do people with more severe gum disease or tooth infection have a higher number of bacteria in their carotid plaques, and are those plaques more likely to rupture? Are the bacteria found in vulnerable plaques different from those in stable plaques? Are similar bacteria found in the mouth, gut, and plaques, suggesting that bacteria may travel through the body? What participants will do: Have their oral health checked before surgery, including an exam of gum disease and tooth infections. Provide microbiome samples from the mouth, anus, urine, and carotid plaque (taken during surgery). Have preoperative photon-counting computed tomography (CT) performed to assess plaque stability and study eligibility. All samples and imaging data will be analyzed to identify bacterial species and their relationship to plaque type. The study does not involve any experimental treatment or medication. Participation adds no significant medical risk beyond standard care. Researchers will compare bacterial patterns between people with vulnerable plaques and those with stable plaques to identify microbial signatures linked to carotid plaque instability. The results may help create future microbiome-based risk models for detecting people at higher risk of stroke or severe atherosclerosis.

Начало: 01.11.2025 Край: 01.11.2029 Възраст: от 18 г.

Hungary Semmelweis University Heart and Vascular Center NCT07296965

Recruiting Phase 1/2

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Colorectal Cancer (Diagnosis) Colorectal Cancer Metastatic Colorectal Cancer (CRC) Immunotherapy

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg IV infusion and bevacizumab 7.5 mg/kg IV infusion Q3W, in participants with pMMR/non-MSI-H colorectal cancer (CRC). It will also determine the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) of ABT-301. Participants will receive ABT-301 administered once daily (QD ±3 hours) or twice daily (Q12H ±3 hours, at least 9 hours apart) with water in 21-day treatment cycles. Tislelizumab 200 mg IV and bevacizumab 7.5 mg/kg IV Q3W will be given in both parts of the study.

Начало: 01.11.2025 Край: 01.07.2028 Възраст: от 18 г. Treatment

Australia, Taiwan Anbogen Therapeutics, Inc. NCT07244705

Recruiting Phase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Peripheral Arterial Disease

The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.

Начало: 31.10.2025 Край: 01.06.2028 Възраст: от 18 г. Treatment

Argentina, Australia, Brazil +13 Eli Lilly and Company NCT07223593

Recruiting Phase 3

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Non-small Cell Lung Cancer (NSCLC)

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

Начало: 31.10.2025 Край: 29.01.2029 Възраст: от 18 г. Treatment

Australia, Belgium, Brazil +16 AstraZeneca NCT07291037

Recruiting Phase 1/2

FACE Phase II (a Stage II Trial)

MCI Subjective Cognitive Decline (SCD) Mild Behavioral Impairment

How to ensure adherence to computerized cognitive training in unsupervised circumstances (e.g., at-home, self-administered) in older adults at risk for Alzheimer's disease (AD) or AD related dementia (AD/ADRD) is understudied. The objective of the R33 study is to test a novel facial expression-based personalization engine (FPE) for monitoring and modulating real-time effective engagement, with an ultimate goal of enhancing long-term adherence in unsupervised cognitive training in older adults at risk for AD/ADRD. Here, Effective engagement is defined as the extent to which someone is actively engaged and performing with significant attention and enjoyment while training, addressing a balance between adherence and cognitive gains/plasticity from the training. Based on previous work, the hypotheses include that (1) mental fatigue revealed in facial expressions will reflect a trainee's degree of effective engagement, which can be modified by modulating task novelty; (2) the proposed FPE will ensure the effective engagement in cognitive training by monitoring trainee facial expressions and modulating training in response, promoting the trainee's long-term adherence to the training and cognitive plasticity. A Stage II intervention efficacy study will be conducted to compare effective engagement and adherence in unsupervised cognitive training between training programs with vs. without FPE in older adults at risk for AD/ADRD. The proposed FPE may assist in monitoring and improving effective engagement and adherence in older adults with unsupervised cognitive training. In the current application, FPE in a cognitive training program called speed of processing training will be tested. However, such FPE may be embedded to any computerized cognitive training in future studies to help address adherence related issues.

Начало: 31.10.2025 Край: 31.08.2028 Възраст: 60–89 г.

United States Stanford University NCT07130669

Recruiting

Decoding Emotional Dynamics in Bipolar Disorder

Bipolar Disorder I or II Healthy (Controls)

The goal of this neuroimaging study is to investigate how emotional states fluctuate in people with bipolar disorder (BD) compared to healthy controls, and to understand the neural mechanisms driving mood instability. The main questions it aims to answer are: * Can emotional states be decoded from fMRI brain activity using machine learning? * Do individuals with BD show more unstable emotional state trajectories (e.g., high metastability, low fractal scaling) than healthy controls? * Does amplifying positive emotions stabilize brain and emotional dynamics in BD? Researchers will compare individuals with bipolar disorder (BD-I or BD-II, currently depressed or mixed state) to healthy controls without psychiatric history to see whether the BD group shows greater fluctuations in emotional brain activity and whether positive emotion regulation strategies normalize this instability. Participants will: * Complete self-report questionnaires on mood, emotion regulation, anxiety, and daily functioning. * Recall and provide short descriptions of personal positive and negative memories to be used in the MRI task. * Undergo fMRI scanning, including: * Resting-state scans * A Think and Regulate Affective States Task (TReAT) where they recall autobiographical memories, rate emotions, and practice amplifying positive mood. * Structural and diffusion MRI for brain mapping. * Receive physiological monitoring (heart rate, respiration) during scanning. * Complete post-scan surveys on emotional state and task experience. This research will help clarify how the brain supports or disrupts emotional regulation in bipolar disorder and may inform the development of personalized, neurobiologically informed treatments for mood instability.

Начало: 30.10.2025 Край: 01.11.2028 Възраст: 18–65 г.

United States Laureate Institute for Brain Research, Inc. NCT07221864

Recruiting Phase 3

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Breast Cancer

A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.

Начало: 30.10.2025 Край: 02.02.2028 Възраст: от 18 г.

China, France, Italy +3 AstraZeneca NCT07205822

Recruiting

Optimizing Care Transition Process for Older Colorectal Surgery Patients

Colorectal Surgery Care Transition Older Adults (65 Years and Older)

The goal of this study to test if a care transition intervention designed for older colorectal surgery patients would improve outcomes after discharge. It will assess the feasibility of the intervention.

Начало: 30.10.2025 Край: 01.12.2027 Възраст: от 65 г.

United States Massachusetts General Hospital NCT06752031

Recruiting Phase 4

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Diabetes Mellitus Type 2 DM

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Начало: 30.10.2025 Край: 30.06.2026 Възраст: 18–80 г.

Pakistan Nabiqasim Industries (Pvt) Ltd NCT06862739

Recruiting

Well-being in IBS: Strengths and Happiness (WISH) 2.0

Irritable Bowel Syndrome

The purpose of this study is to examine the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of an optimized positive psychology (PP) intervention for patients with irritable bowel syndrome (IBS), entitled "WISH," compared to an educational control intervention.

Начало: 30.10.2025 Край: 01.08.2028 Възраст: от 18 г.

United States Massachusetts General Hospital NCT06866106

Recruiting Phase 3

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Breast Neoplasms

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatments the participants actually receive. Participants will receive either the trial drug with chemotherapy or placebo (which looks like the trial drug but does not have any drug in it) with chemotherapy.

Начало: 30.10.2025 Край: 01.09.2030 Възраст: от 18 г. Treatment

Australia, Belgium, China +9 BioNTech SE NCT07173751

Recruiting Phase 2

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

Pompe Disease

The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.

Начало: 30.10.2025 Край: 08.08.2027 Възраст: от 18 г.

Belgium, Denmark, France +6 Shionogi NCT07123155

Recruiting

ADHERE Trial: Strategies to Improve Mobile App Adherence

Low Back Pain

This study aims to evaluate the effectiveness of two communication interventions, compared to standard app notifications, in increasing adherence to a mobile health app among individuals with chronic low back pain. The main question it aims to answer is: Do phone calls or text messages increase adherence compared to app notifications in patients receiving a digital health intervention for chronic back pain? Participants will: A) Receive pain education and clinical hypnosis via a mobile app for managing chronic LBP; B) Will be contacted up to twice via phone call or text message, or they will only receive standard notifications from the app.

Начало: 30.10.2025 Край: 26.05.2028 Възраст: от 18 г. Treatment

Australia Neuroscience Research Australia NCT07205991

1 … 63 64 65 66 67 … 222